Abstract: Compositions and methods for treating and preventing arthropod infestation are disclosed. A method of treating an arthropod infestation in a subject in need thereof, the method comprising administering topically to the subject an effective amount of either an insecticidal composition consisting essentially of at least one essential oil and a pentacyclosiloxane or an insecticidal composition comprising at least one essential oil, a pentacyclosiloxane, and a mineral oil.

Abstract: The present invention features novel cosmetic skin care compositions for improving the appearance of skin, particularly the reducing the appearance of age spots and discoloration.

Abstract: The present invention relates to an adhesive and soluble adhesive bandage or patch comprising a soluble film of natural origin with high mineral content. The soluble film comprises from 20 to 90 wt % of mineral filler and wherein the mineral filler content level is higher than the polysaccharide content level. It also relates to these bandages or patches for use in cosmetics or therapy.

Abstract: The invention relates to a cosmetic product, comprising a) a cosmetic preparation, containing, in relation to its total weight, a1) about 45 to about 98 wt. % of at least one polar solvent; a2) about 0.5 to about 15 wt. % of at least one copolymer from the monomers i) n-tert-octylacrylamide, ii) acrylic acid, iii) tert-butylamino ethyl methacrylate, iv) and optionally other monomers; b) a device for flash evaporation of the cosmetic preparation a), and to a method using corresponding products and to the use of the cosmetic preparation a) as process material in a device for flash evaporation.

Abstract: Provided herein long lasting cosmetic compositions and markers for selecting the same.

Abstract: An aqueous cleansing composition comprises at least one amino acid surfactant, an aqueous non-ionic emulsion of divinyldimethicone/dimethicone copolymer, and at least one additional anionic surfactant, other than the at least one amino acid surfactant, wherein the at least one amino acid surfactant comprises at least one glutamate surfactant according to the general formula wherein R1 is a saturated or unsaturated, straight or branched alkyl chain with 7 to 17 carbon atoms, and M is independent from each other H, sodium or potassium, and optionally at least one sarcosinate surfactant according to the general formula wherein R1 is a saturated or unsaturated, straight or branched alkyl chain with 7 to 17 carbon atoms, and M is H, sodium or potassium, and further wherein the aqueous cleansing composition is an aqueous hair cleansing composition.

Abstract: The present invention provides a process for making a bi-modal water continuous emulsion comprising forming a mixture comprising 100 parts by weight of a hydrophobic oil and 1 to 1000 part by weight of a water continuous emulsion having at least one surfactant, and admixing additional quantities of the water continuous emulsion and/or water to the mixture to form a bi-modal water continuous emulsion, wherein the water continuous emulsion forms a first dispersed phase of particle size P1 and the hydrophobic oil forms a second dispersed phase of particle size P2, and wherein the ratio P2:P1 is less than 1. The present invention provides bi-modal water continuous emulsion having a first dispersed phase of particle size P1 and a second dispersed phase of particle size P2 wherein the ratio P2:P1 is less than 1, and personal care and coating compositions comprising the bi-modal water continuous emulsion.

Abstract: Ionic and ionogenic comb copolymers are disclosed along with personal care products that employ them as a modifier that results in increased sensory attributes and increased effectiveness in the deposition of actives and can also act as a thickening agent. The copolymer includes one or more repeating units derived from olefinically unsaturated anionic or anionogenic or zwitterionic comonomers, and one or more repeating units having the formula in which Y is a moiety forming part of a copolymer backbone, Z is a moiety that exhibits association with other Z moieties or with other moieties within the ultimate formulation in which the copolymer will be employed, and b is a bond or moiety that links the Z moiety to the Y moiety. In certain embodiments, the copolymer also includes repeating units derived from acrylamide monomers, olefinically unsaturated hydrophilic monomers or other olefinically unsaturated monomers.

Abstract: The present invention relates to a cosmetic composition for making up and/or caring for the skin and/or the lips, including, in a physiologically acceptable medium, at least one oil, which is preferably non-volatile, at least hydrophobic silica aerogel particles, at least one hydrocarbon-based block copolymer, preferably obtained from at least one styrene monomer, the said composition comprising less than 5% by weight of water relative to the total weight of the composition, and preferably being anhydrous.

Abstract: A rose-petal body wash which comprises the following raw materials by mass percentage: solvent, suspending agent, thickener, humectant, odorant, neutralizer, emollient, chelating agent, preservative, color stabilizing agent, colorant, and its preparation method which comprises the following steps: (1) clean an agitator kettle completely and clean up the rose petals in advance; (2) pump in de-ionized water and start agitation, then feed partial raw materials in turn, then heat them up to 85° C. and agitate to dissolve completely, (3) after the raw materials dissolve, cool the system down to 50° C. and add NaOH solution to adjust it to a transparent solution, then add some other raw materials, (4) cool the system to 45° C., then add the remaining raw materials and adjust to an acceptable color before discharging, (5) discharge and inspect the product, if it is acceptable, store as finished product.

Abstract: Disclosed herein are cosmetic lip compositions that contain dried food powders. The dried food powders are present in about 1% to about 20% and impart flavor to the lip compositions. The lip compositions can be solid (e.g., balms, lipsticks) or semi-solid (e.g, gels in tubes) and can be made using known manufacturing processes.

Abstract: Disclosed is a topical skin composition comprising an aqueous extract from a part of Nymphaea gigantea, wherein said part consists of the flower of Nymphaea gigantea, an aqueous extract from a part of Plumeria alba, wherein said part consists of the flower of Plumeria alba, and a dermatologically acceptable vehicle.

Abstract: The present invention relates to a microorganism belonging to the group of lactic acid bacteria characterized in that it is capable of specifically binding to Streptococcus mutans, wherein the specific binding is (i) resistant to heat treatment; and/or (ii) resistant to protease treatment; and/or (iii) calcium-dependent; and/or (iv) formed within a pH range between 4.5 and 8.5; and/or (v) formed in the presence of saliva. Preferably, the specific binding can be assayed as follows: (a) growing said microorganism to stationary phase; (b) mixing said microorganism with Streptococcus mutans which has been grown to stationary phase; (c) incubating the mixture obtained in step (b) under conditions allowing the formation of aggregates of said microorganism and Streptococcus mutans and (d) detecting aggregates by the occurrence of a pellet.

Abstract: A method of treating a person's skin comprising topically applying to skin a composition that includes an effective amount of a hydrolyzed algae extract that includes an exopolysaccharide from Halymenia durvillei and an effective amount of an exopolysaccharide from Vibrio alginolyticus. Topical application of the composition can decrease skin permeability, increase filaggrin production, increase skin moisture, increase occludin production, and/or decrease TNF-? production.

Abstract: An oral film product in which a pharmaceutically active agent is stabilized in its partially-ionized form to better facilitate oral transmucosal delivery is provided. The film includes a bioadhesive layer including a pharmaceutically active agent having a logarithmic acid dissociation constant that is less than 4.5 and which is complexed with a cationic polymer.

Abstract: The present invention relates to fatty acid acylated amino acids (FA-Daa's) acting as permeation enhancers for oral delivery of therapeutic macromolecules such as peptides and pharmaceutical compositions comprising such FA-Daa's.

Abstract: A microneedle device includes a substrate; a microneedle projecting from the substrate and configured to be inserted into skin; and a drug coating the microneedle. An aspect ratio of a maximum width of a base of the microneedle to a height of the microneedle is equal to or greater than 2.1.

Abstract: A microneedle patch includes a base, at least one collapsible side wall extending from the base, and a lip disposed along the at least one collapsible sidewall and opposite the base. An adhesive is disposed along the base, and a microneedle array is affixed to the base.

Abstract: A method of selectively targeting a cell with a therapeutic agent, the method comprising: targeting a cell with a nanospear, puncturing the cell with said nanospear; releasing a therapeutic agent from said nanospear, wherein said therapeutic agent enters said cell, thereby effecting the efficacy of said cell.

Abstract: Oral liquid colchicine formulations are described herein. Methods of using the oral liquid colchicine formulations are also provided.

Abstract: The present invention provides a cancer treatment method in which side effects are inhibited. Specifically, in a combination therapy of a high intensity focused ultrasound therapy at an irradiation intensity of 320 to 700 W/cm2 and an anti-cancer agent therapy, an anti-cancer agent containing an anthracycline is used such that the anthracycline in a dose of 0.5 to 7.5 mg/kg body weight is administered to a cancer patient.

Abstract: The present invention relates to a pharmaceutical composition comprising the combination of (i) at least two distinct biocompatible nanoparticles and (ii) at least one compound of interest, typically at least one pharmaceutical compound, to be administered to a subject in need of such at least one compound of interest, wherein the at least two distinct biocompatible nanoparticles potentiate the compound(s) of interest efficiency. The at least two biocompatible nanoparticles can be administered sequentially or simultaneously to the subject but are to be administered separately, typically with an interval of between more than about 5 minutes and about 72 hours, from the at least one compound of interest, preferably before the administration of the at least one compound of interest, to said subject. The longest dimension of the at least two biocompatible nanoparticles is typically between about 4 nm and about 500 nm.

Abstract: The present invention relates to a pharmaceutical composition comprising the combination of (i) at least one biocompatible nanoparticle and (ii) at least one pharmaceutical compound, to be administered to a subject in need of such a pharmaceutical compound, wherein the nanoparticle potentiates the pharmaceutical compound efficiency. The longest dimension of the biocompatible nanoparticle is typically between about 4 and about 500 nm, its absolute surface charge value is of at least 10 mV (|10 mV|), and its Young modulus is less than 100 kPa. The invention also relates to such a composition for use for administering the pharmaceutical compound in a subject in need thereof, wherein the at least one nanoparticle and the at least one pharmaceutical compound are to be administered in the subject between more than 5 minutes and about 72 hours one from each other.

Abstract: The present invention provides apparatus and processes for producing liposomes. By providing a buffer solution in a first reservoir, and a lipid solution in a second reservoir, continuously diluting the lipid solution with the buffer solution in a mixing chamber produces a liposome. The lipid solution preferably comprises an organic solvent, such as a lower alkanol.

Abstract: The present disclosure generally relates to the field of medicine. The present invention more specifically relates to a pharmaceutical composition comprising the combination of (i) at least one biocompatible nanoparticle comprising, or consisting in, at least one natural compound which is an inhibitor of a human CYP enzyme, the longest dimension of said nanoparticle being of at least 4 nm and less than 100 nm, and (ii) at least one compound of interest, typically at least one pharmaceutical compound, to be administered to a subject in need of such at least one compound of interest, wherein the combination of the at least one biocompatible nanoparticle and of the at least one compound of interest potentiates the at least one compound of interest's bioavailability.

Abstract: The present invention relates to a pharmaceutical composition comprising the combination of (i) at least one biocompatible nanoparticle and (ii) at least one carrier comprising at least one pharmaceutical compound, to be administered to a subject in need of such a pharmaceutical compound, wherein the combination of the at least one biocompatible nanoparticle and of the at least one carrier comprising the pharmaceutical compound(s) potentiates the compound(s) of interest efficiency. The longest dimension of the biocompatible nanoparticle is typically between about 4 and about 500 nm and its absolute surface charge value is of at least 10 mV (|10 mV|). The carrier is in addition devoid of any surface sterically stabilizing agent.

Abstract: Provided herein is technology relating to liposomes and particularly, but not exclusively, to compositions of liposomes encapsulating a biologically active agent, methods of preparing liposomes encapsulating a biologically active agent, and uses of liposomes encapsulating a biologically active agent to treat a subject.

Abstract: [Object] An object of the present invention is to provide an oral solid preparation that can be produced in a simpler manner than conventional methods, that exhibits high bioavailability and high dissolubility even in persons having low stomach acid, and that can also ensure dissolubility after being allowed to stand for a certain period of time. Another object is to provide a simple method for producing the oral solid preparation.

Abstract: This invention relates to nanomedical technologies, namely to the fabrication of nanocarriers of drugs for antitumor chemotherapy. The technical result of the invention consists of increasing the efficiency of antitumor chemotherapy by increasing the activity of the cell absorption of nanocontainers loaded with an antitumor drug, avoiding of the nanocontainer toxicity for cells due to the use of dispersed boron nitride nanoparticles of 50-300 nm in diameter with a well-developed outer surface. The method of boron nitride nanoparticles fabrication for antitumor drug delivery to tumor cells includes synthesis of spherical boron nitride nanoparticles of 50-300 nm in diameter with a well-developed outer surface by chemical vapor deposition using ammonia reaction gas, argon transport gas and powder mixture composed of amorphous boron and oxidizing reactants.

Abstract: The invention provides ingestible particles comprising a water-swellable or water-soluble polymeric component, a lipid component, and optionally an amino acid, a vitamin and/or a micro-nutrient. The polymeric component may be embedded in the lipid component. The particle may further comprise an inert core and/or an outer layer which rapidly disintegrates after oral ingestion. The invention further provides methods for preparing the ingestible particles and uses thereof.

Abstract: The present invention relates to a process for spray-freeze-drying (SFD) a dispersion of polyelectrolyte complex (PEC) nanoparticles loaded with a protein drug, which yields a powdered product with adequate flowability properties that may readily be processed further into solid dosage forms such as tablets or capsules. The mean particle size of PEC nanoparticles obtained after redispersion of SFD powder or pharmaceutical compositions made from said powder in water is preserved in the nanometer range (<1000 nm), and so is the protein biological activity.

Abstract: Disclosed herein, are methods of preparing fetal support tissue powders. Further disclosed herein, are methods of using the fetal support tissue powder product.

Abstract: The present invention relates to a cellulose powder usable for a satisfactory orally disintegrating tablet having excellent compression moldability and well-balanced tablet moldability and disintegration properties, which can obtain excellent ingestion feel without feeling roughness and dryness in the oral cavity, and more particularly to a cellulose powder with an average polymerization degree of 150 to 450, an average particle diameter of not less than 10 ?m but less than 100 ?m, and a primary particle ratio of 50% or more.

Abstract: Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.

Abstract: A method of forming an erodible sustained release tablet comprising the steps of:—a. mixing one or more therapeutic agents, one or more disintegrant and one or more molten wax, whilst retaining the wax in molten form; b. solidifying and granulating the mixture; c. forming a tablet by compression of the granules. The invention also relates to a sustained release tablet made according to the method.

Abstract: Embodiments provide swallowable devices, preparations and methods for delivering viable cells (VC) into the GI tract including GI wall tissue or other tissue site. Particular embodiments provide a swallowable device such as a capsule for delivering VC into an intestinal wall or other site. The VC can be contained within a tissue-penetrating shell disposed in the capsule that protects the VC as they pass through the GI tract until they are inserted into GI tract tissue or other location. The shell desirably has shape, size and material consistency to be contained in a swallowable capsule, delivered from the capsule into solid tissue by the application of force on the shell and biodegrade within the solid tissue to release the VC into the tissue. Within the shell or other structure the VC can be maintained in a viability-sustaining gel that preserves the viability of the VC for selected time periods.

Abstract: This present invention discloses hydroxypropyl starch vacant capsules and a process for producing them, wherein said hydroxypropyl starch vacant capsules are made of hydroxypropyl starch and water and optional light-screening agent, colorant, aromatics, and flavoring agent through the processes of raw material mixup, gelatinization, stabilization, and capsule-forming. The hydroxypropyl starch capsules disclosed in this invention have such advantages as extensive source of raw material, high safety level, disintegrating property and friability over the products prepared through existing technologies.

Abstract: Intact, bacterially-derived minicells can safely introduce therapeutically effective amounts of plasmid-free functional nucleic acid to target mammalian cells. To this end, functional nucleic acid can be packaged into intact minicells directly, without resort to expression constructs, the expression machinery of the host cell, harsh chemicals or electroporation.

Abstract: Provided are co-assembled nanoparticles including at least one polypeptide including a polyanion; and at least one amphiphilic peptide capable of forming a ?-sheet structure, a derivative or a salt thereof, the amphiphilic peptide including at least 2 pairs of alternating hydrophobic/hydrophilic amino acid residues in which the hydrophilic amino acid residue is positively charged, and methods of preparation of the nanoparticles. Further provided are pharmaceutical compositions including the co-assembled nanoparticles and a pharmaceutically active ingredient, dissolved, entrapped, encapsulated or attached to the co-assembled nanoparticles. Further provided are therapeutic uses of the pharmaceutical compositions.

Abstract: The present invention provides a nano-particle based structure or composition for a combinational cancer therapy. The structure has a doxorubicin (DOX) physically loaded on core-shell silver polymeric nanoparticles (AgN-Ps) with a ratio of 3.3-5.5% doxorubicin to 1% silver to 2-10% polymer. This structure enhances the cellular uptake of DOX in comparison to the current conventional combination therapy. The DOX-loaded nano-particles result in an improved the therapeutic efficiency of DOX, and reduced its toxicity, which cannot occur in case of adding DOX and AgNPs.

Abstract: The present invention relates to polymeric structures, in the form of flat membrane-like surfaces or micro- nanostruc-tures such as capsules, characterized in that it comprises a substantially two-dimensional layer of covalently-bonded monomers of R-substituted metal or metalloid oxides. Said polymeric structures in most embodiments have a crystal architecture with a hexagonal lattice, but the nature of the covalent bonds present therein impart a bending flexibility that make the polymeric structures behave as a “soft” crystal. Methods of producing such structures, composition comprising thereof and method of using thereof are also included within the present disclosure.

Abstract: The present invention provides, among other things, multilayer film coating compositions, coated substrates and methods thereof. In some embodiments, a structure, comprising a substrate and a multilayer film on the substrate, wherein the multilayer film comprises a release layer and one or more layer-by-layer films. In some embodiments, a structure comprising a microneedle substrate and a multilayer film coated on at least portion of the microneedle substrate, wherein the multilayer film comprises an agent for delivery.

Abstract: A medicament for accelerated wound healing is proposed containing derivatives of the formula (I), in which R1 stands for hydrogen or methyl.

Abstract: Provided herein are compositions for the treatment and/or prevention of cardiovascular disease (CVD), and methods of application and use thereof. In particular, the present invention provides treatment and/or prevention of cardiovascular disease with compounds that inhibit the production of TMA in the gut, such as 3,3-dimethyl-1-butanol (DMB) or other compounds represented by Formula I or as shown in FIGS. 20-23.

Abstract: The invention relates to (i) 6-membered heteroaryl substituted fatty acid cystamine conjugates, compositions thereof, methods of treating diseases involving dysregulation of autophagy, such as cystic fibrosis, idiopathic pulmonary fibrosis (IPF), a neurodegenerative disease, inflammatory disease, liver disease, muscle disease, infection and immune disease with this compound, or (ii) a method of treating idiopathic pulmonary fibrosis, mitochondrial diseases, Leigh Syndrome, Diabetes Mellitus and Deafness (DAD), Leber's hereditary optic neuropathy, Neuropathy-ataxia-retinis pigmentosa and ptosis (NARP), myoneurogenic gastrointestinal encephalopathy (MNG1E), myoclonic epilepsy with ragged red fibers (MERRF), or mitochondrial myopathy-encephalomy-opathy-lactic acidosis stroke like symptoms (MELAS), comprising administering to a patient the fatty acid cysteamine conjugate, (4Z, 7Z.

Abstract: Provided is an agent for reducing odors of pyrazine derivatives based on an olfactory receptor antagonism. The agent for reducing odors of pyrazine derivatives includes at least one antagonist of olfactory receptor OR5K1 as an active ingredient.

Abstract: The present invention discloses a process for preparation of white curcumin from purified curcuminoids. The curcuminoids are obtained by solvent extraction and crystallization of dried turmeric powder. The autoclave is charged with ethyl acetate and the 95% purity curcuminoids mixture is added to and stirred for uniformity at room temperature. 5% (w/w) of 10% palladium carbon is added to the reaction mixture and allowed for hydrogenation in the presence of hydrogen gas at 2 lbps pressure and stirred continuously for 15 hours. Once the reaction is completed, the reaction mixture is filtered and washed with ethyl acetate. The ethyl acetate is distilled off and crude mass is stirred with water to obtain a solid precipitate. Finally, the solid obtained is filtered and dried to pale brown crystals of white curcumin. White curcumin is encapsulated with beta-cyclodextrin, which exhibited increased bioavailability. White curcumin also exhibited anti-oxidant and chemopreventive activities.

Abstract: Disclosed herein are naphthoquinone analogs, such as plumbagin, pharmaceutical compositions that include naphthoquinone analogs, such as plumbagin, and methods of treating diseases and/or conditions such as cancer with naphthoquinone analogs, such as plumbagin. Also included are combination therapies wherein a naphthoquinone analog, such as plumbagin, and a hormone therapy agent are provided to a subject suffering from a condition such as cancer.

Abstract: Ketogenic compositions including a beta-hydroxybutyrate (BHB) mixed salt are formulated to induce or sustain ketosis in a subject to which the ketogenic compositions are administered. The BHB mixed salt is formulated to provide a biologically balanced set of cationic electrolytes, and is formulated to avoid detrimental health effects associated with imbalanced electrolyte ratios. A ketogenic composition includes BHB salts of at least sodium, potassium, calcium, and magnesium. The BHB salts may also include at least other component such as a BHB compound containing other cations, such as transition metal cations (e.g., zinc or iron), a BHB-amino acid salts, medium chain fatty acid source, vitamin D3, flavorant, or other excipient.